Heidelberg Materials Bangladesh PLC. (DSE:HEIDELBCEM)
Bangladesh · Delayed Price · Currency is BDT 253.40
+8.40 (3.43%)
At close: Jul 31, 2025
Ligand Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is January - December.
Millions BDT. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 14,213 | 14,740 | 17,956 | 16,767 | 14,328 | 11,681 | Upgrade | |
Revenue Growth (YoY) | -10.99% | -17.91% | 7.09% | 17.02% | 22.66% | -2.55% | Upgrade |
Cost of Revenue | 12,592 | 12,945 | 15,895 | 15,698 | 12,737 | 10,333 | Upgrade |
Gross Profit | 1,621 | 1,796 | 2,061 | 1,069 | 1,591 | 1,348 | Upgrade |
Selling, General & Admin | 1,180 | 1,135 | 1,228 | 1,084 | 931.18 | 996.69 | Upgrade |
Other Operating Expenses | -4.13 | -7.35 | -14.17 | -13.61 | -8.16 | -13.43 | Upgrade |
Operating Expenses | 1,176 | 1,127 | 1,214 | 1,071 | 923.02 | 983.26 | Upgrade |
Operating Income | 445.12 | 668.18 | 846.36 | -1.86 | 668.4 | 365.02 | Upgrade |
Interest Expense | -169.98 | -258.24 | -288.22 | -77.94 | -61.05 | -184.92 | Upgrade |
Interest & Investment Income | 277.18 | 333.45 | 234.9 | 13.36 | 61.53 | - | Upgrade |
Currency Exchange Gain (Loss) | -1.84 | -1.72 | -2.75 | -5.68 | -1.96 | - | Upgrade |
Other Non Operating Income (Expenses) | -12.31 | -12.31 | -4.94 | 1.12 | - | - | Upgrade |
EBT Excluding Unusual Items | 538.18 | 729.36 | 785.35 | -71 | 666.92 | 180.1 | Upgrade |
Gain (Loss) on Sale of Assets | -2.67 | -2.67 | 1.26 | -8.82 | - | - | Upgrade |
Other Unusual Items | - | - | - | -0.38 | - | - | Upgrade |
Pretax Income | 535.51 | 726.69 | 786.62 | -80.2 | 666.92 | 180.1 | Upgrade |
Income Tax Expense | 271.89 | 264.9 | 327.21 | 153.25 | 191.63 | 260.94 | Upgrade |
Net Income | 263.61 | 461.79 | 459.41 | -233.44 | 475.28 | -80.84 | Upgrade |
Net Income to Common | 263.61 | 461.79 | 459.41 | -233.44 | 475.28 | -80.84 | Upgrade |
Net Income Growth | -34.52% | 0.52% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade |
Shares Outstanding (Diluted) | 57 | 57 | 57 | 57 | 57 | 57 | Upgrade |
EPS (Basic) | 4.67 | 8.17 | 8.13 | -4.13 | 8.41 | -1.43 | Upgrade |
EPS (Diluted) | 4.67 | 8.17 | 8.13 | -4.13 | 8.41 | -1.43 | Upgrade |
EPS Growth | -34.52% | 0.52% | - | - | - | - | Upgrade |
Free Cash Flow | 291.42 | 1,781 | 1,022 | -8.68 | 856.16 | 1,192 | Upgrade |
Free Cash Flow Per Share | 5.16 | 31.52 | 18.08 | -0.15 | 15.15 | 21.10 | Upgrade |
Dividend Per Share | 2.500 | 2.500 | 2.500 | 1.000 | 2.600 | 2.000 | Upgrade |
Dividend Growth | - | - | 150.00% | -61.54% | 30.00% | - | Upgrade |
Gross Margin | 11.40% | 12.18% | 11.48% | 6.38% | 11.11% | 11.54% | Upgrade |
Operating Margin | 3.13% | 4.53% | 4.71% | -0.01% | 4.67% | 3.13% | Upgrade |
Profit Margin | 1.85% | 3.13% | 2.56% | -1.39% | 3.32% | -0.69% | Upgrade |
Free Cash Flow Margin | 2.05% | 12.08% | 5.69% | -0.05% | 5.97% | 10.21% | Upgrade |
EBITDA | 783.84 | 1,066 | 1,259 | 437.52 | 1,063 | 828.12 | Upgrade |
EBITDA Margin | 5.51% | 7.23% | 7.01% | 2.61% | 7.42% | 7.09% | Upgrade |
D&A For EBITDA | 338.72 | 397.91 | 412.2 | 439.38 | 394.41 | 463.11 | Upgrade |
EBIT | 445.12 | 668.18 | 846.36 | -1.86 | 668.4 | 365.02 | Upgrade |
EBIT Margin | 3.13% | 4.53% | 4.71% | -0.01% | 4.67% | 3.13% | Upgrade |
Effective Tax Rate | 50.77% | 36.45% | 41.60% | - | 28.73% | 144.89% | Upgrade |
Advertising Expenses | - | 136.06 | 205.98 | 184.99 | 111.27 | 90.41 | Upgrade |
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.